INTERIM HIGHLIGHTS
- Cephalon, Inc (Cephalon), ImmuPharma’s licensee for Rigerimod (LupuzorTM), continues to progress its Phase IIb trial in US and European lupus patients. This study has been designed to provide US-based investigators and the US FDA with clinical data obtained mainly in the USA. This data will be part of the package submitted to the FDA and other regulatory authorities for approval. We plan to provide an update on this trial in conjunction with Cephalon announcing these results. Positive Phase IIb data from outside the USA has previously been announced. ImmuPharma look forward to providing an update on LupuzorTM’s progress following the finalisation of the acquisition of Cephalon by Teva Pharmaceuticals.
- The Phase I/IIa trial of IPP-204106, ImmuPharma’s anti-cancer compound with a novel and promising mechanism of action, continues to progress in cancer patients. A scientific paper on IPP-204106 was published in the prestigious medical journal of the American Association for Cancer Research
- Strong cash position of £14.3m
- Basic and diluted loss per share were 2.59p and 2.59p respectively (30 June 2010: basic and diluted loss per share 0.10p and 0.10p respectively)
Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said:
“The first half of 2011 has seen ImmuPharma build on the success of 2010 with Cephalon, our licensee for LupuzorTM, moving ahead with a large trial in the US. We look forward to providing an update on LupuzorTM’s progress once Teva’s acquisition of Cephalon is complete. In parallel, we are focusing our own efforts on our promising cancer drug and are pleased to have seen encouraging results so far and to have achieved publication in the journal of the American Association for Cancer Research. We look forward to building on this success during the rest of 2011 and in the coming years.”
Richard Warr, ImmuPharma’s Chairman added:
“ImmuPharma has two potential blockbuster drugs in the clinic, LupuzorTM and our cancer compound, IPP-204106. We look forward to providing an update on LupuzorTM following the imminent finalisation of Teva’s acquisition of Cephalon. Moreover, ImmuPharma is pleased to report a strong balance sheet, controlled expenditure and a robust cash position.”
For further information, please contact:
ImmuPharma PLC:
Dimitri Dimitriou, Chief Executive Officer
+44 20 7152 4080
Richard Warr, Chairman
Tracy Weimar, VP, Operations
Buchanan Communications
Lisa Baderoon, Mark Court
+44 20 7466 5000
Panmure, Gordon & Co., NOMAD & Broker
Andrew Burnett
+44 20 7459 3600
Espirito Santo Investment Bank, Joint Broker
James Bromhead
+44 20 7456 9191
